Clinical Trial

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

Study acronym: PROSTEP-002
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per institutional standard of care conventional imaging
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-11-30; most recent amendment 2025-12-17.
Status change: Recruiting → Active, Not Recruiting 2025-05-12
Status change: Not Yet Recruiting → Recruiting 2022-03-29
Trial Details
NCT Number NCT04655365
Lead Sponsor CHU de Quebec-Universite Laval
Collaborators: Astellas Pharma Europe Ltd.
Conditions Prostate Cancer
Enrollment 50 participants
Start Date 2022-03-22
Primary Completion 2025-11-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-23